30 results on '"Eisenhauer, Elizabeth A."'
Search Results
2. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer
3. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer
4. A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study
5. Establishment of a Low Birth Weight Registry and Initial Outcomes
6. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation
7. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)
8. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial
9. Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)
10. A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours
11. A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145
12. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study
13. Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma
14. Phase II Trial of SarCNU in Malignant Glioma: Unexpected Pulmonary Toxicity with a Novel Nitrosourea
15. New guidelines to evaluate the response to treatment in solid tumors
16. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
17. Phase I and Pharmacokinetic Study of Fostriecin given as an Intravenous Bolus Daily for Five Consecutive Days
18. A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma
19. Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks
20. Phase II Study of Marimastat (BB-2516) in Malignant Melanoma – A Clinical and Tumor Biopsy Study of the National Cancer Institute of Canada Clinical Trials Group
21. A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity
22. The Taxoids
23. Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer
24. Phase II study of elsamitrucin in non-small cell lung cancer
25. Phase I pharmacokinetic study of DUP-937, a new anthrapyrazole
26. Phase II study of tiazofurin in gliomas in adults
27. Phase II study of 2′-deoxycoformycin in patients with renal cell carcinoma
28. A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma
29. A phase II study of spirogermanium in patients with metastatic malignant melanoma
30. Hypersensitivity reactions to deoxycoformycin
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.